Goodwin Manufactures Neogenix MAb for Trial

Goodwin Biotechnology, Inc. (GBI) completed the first phase of manufacturing of Neogenix Oncology’s monoclonal antibody, NPC-1C. The product has been delivered to Neogenix in preparation for Phase I/II trials planned for the first half of the year.

Neogenix portfolio includes MAbs that recognize cancer-specific immunogenic proteins derived from specific tumor systems. Neogenix monoclonal antibodies define the immunogenic tumor protein as both a diagnostic marker and as a therapeutic target for tumor destruction. NPC-1C is intended for the treatment of advanced pancreatic cancer, and is the first of these products to enter development. Anti-tumor activity has been demonstrated both in-vitro ADCC assays and recently completed animal studies.

“Completion of this phase of development with NPC-1C represents an important milestone for our company,” said Philip M. Arlen, M.D., Neogenix’s president and chief medical officer. “The team at Goodwin has done an excellent job in delivering a high quality antibody that with FDA approval, will allow us to enter our Phase I/II trials.”

Stephanie Finnegan, chief executive officer of GBI, commented, “While it is never easy to bring a novel molecule from the research bench into human clinical trials, the professionalism, scientific skills, good business practices and partnering spirit of the Neogenix team have facilitated our work immensely. Our team has been highly motivated to perfect the clinical manufacturing of a promising therapy for what is a devastating disease. It has been a privilege to work with Neogenix on this break-through project.”